Document Detail


Atherosclerotic plaque regression - the role of statin therapy.
MedLine Citation:
PMID:  20830320     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Increasing knowledge of the atherosclerotic process, as well as atherosclerotic plaque composition and morphology, has lead to the identification of vulnerable plaques that lead to acute coronary syndromes. There is growing evidence for atherosclerotic plaque regression, which makes an aggressive targeted therapeutic response based on achieving plaques regression necessary in order to reduce the significant mortality and morbidity associated with coronary heart disease. This review will examine the evidence for atherosclerotic plaque regression, the important role of statins and the available imaging techniques used to investigate this condition. We will also discuss future evolving therapies and possible predictors of plaque regression, which may aid the therapeutic process.
Authors:
P Sastry; J C Kaski
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  46     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-09-10     Completed Date:  2010-12-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  601-8     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
Affiliation:
Division of Cardiac and Vascular Sciences, St. George's University of London, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Atherosclerosis / complications,  drug therapy*,  pathology
Coronary Artery Disease / etiology,  pathology,  prevention & control*
Disease Progression
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria.
Next Document:  A report from the 106th International Conference of the American Thoracic Society (May 14-19, 2010 -...